CANCELLED: 7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology
Not eligible for ESCO credits
14.05.2020 - 19.05.2020
Vodice, Croatia
MASTERCLASS
Important information
On behalf of ESO and ESMO, we would like to inform you that due to the ongoing Coronavirus (COVID-19) crisis we have made the difficult decision to cancel the 7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology, 14-19 May 2020, Vodice, Croatia.
We deeply regret having to take this decision but we feel that in the current climate we all need to do our part in trying to limit the diffusion of the virus as much as possible and this was the only decision possible considering your role in society as medical staff.
We have discussed the possibility of postponing the event to later this year, but due to other already planned activities we have decided that postponing is not a viable solution.
We apologize for any inconvenience caused but we think you’ll all agree that this solution was unavoidable.
Description
Chairs: A. Eniu, CH - C. Zielinski, AT
Host chair: E. Vrdoljak, HR
ESO Masterclass Coordinator: N. Pavlidis, GR
INTRODUCTION
This residential programme has been designed for medical and clinical oncologists, who wish to improve their skills or those who are preparing for the national board or ESMO exam. The programme will expose participants to a full spectrum of issues in clinical and medical oncology from basic science to advanced knowledge of systemic therapy as well as in the multidisciplinary treatment approach. It is intended to cover all major topics of ESMO-ASCO curriculum on medical oncology.
The programme focuses on cancer pathology and molecular biology, pharmacology of anti-cancer drugs and on frequent cancers such as breast, lung, gastro-intestinal, gynaecological and head and neck cancer. Spotlight sessions will provide inside on state of the art approaches in melanoma, sarcoma, thyroid cancer and on palliative care. Furthermore, practical training will be offered in the frame of clinical case presentations, prepared and presented by the participants and faculty for an interactive discussion.
All participants will reside at the Masterclass venue and participation is mandatory throughout the course. At the end of each of the five days a learning self-assessment discussion with the chair of the course will be provided.
LEARNING OBJECTIVES
• To update the knowledge on basic science of clinical and medical oncology
• To enhance the competence and practical performance in systemic therapy of malignancies
• To enhance the competence and practical performance in multidisciplinary cancer care
• To update knowledge and get additional skills in supportive as well as palliative care
• To prepare for the board exam in clinical/medical oncology
THE MASTERCLASS IS:
• A five day residential, educational event
• Full immersion
• Clinically oriented
• Multidisciplinary
MAIN TOPIC
• Cancer biology/pathology
• Cancer genetics
• Pharmacology of anti-cancer drugs
• Breast cancer
• Gastro-intestinal tumours
• Gynaecological tumours
• Symptom management in gynaecological cancers
• Head and neck cancers
• Lung cancer and mesothelioma
• Genito-urinary cancers
• Palliative and supportive care
• Haematological malignancies
The Eastern Europe |
![]() |
In this review, the authors summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. The MCO has become a major educational event of ESO, intending to educate young oncologists from various countries within or outside Europe, providing an up-to-date interactive program based on solid evidence for all presented topics.
"Reprinted from Critical Reviews in Oncology / Hematology, Pavlidis et al, Copyright (2019)
https://doi.org/10.1016/j.critrevonc.2019.07.022 with permission from Elsevier”
• Download PDF document
Faculty
FACULTY
J. Beyer, University Hospital Zürich, CH
S. Bosnjak, Institute of Oncology and Radiology of Serbia, Belgrade, RS
E. Brain, Marie Curie Institute, Paris, FR
M.J. Cardoso, Champalimaud Cancer Center, Lisbon, PT
S. Cascinu, Università di Modena e Reggio Emilia, Modena, IT
T. Cufer, University Clinic Golnik, Golnik, SI
O. Dafni, National and Kapodistrian University of Athens, Athens, GR
A. Eniu, Riviera-Chablais Vaud-Valais, Rennaz, CH
F.B. Geara, American University of Beirut Medical Center, Beirut, LB
M. Halaska, Charles University, Prague, CZ
M.A. Hoda, Medical University Vienna, Vienna, AT
D. Jovanovic, Clinical Center of Serbia, Belgrade, RS
I. Kern, University Clinic Golnik, Golnik, SI
S. Martin Algarra, University Clinic of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, ES
D. Papamichael, Bank of Cyprus Oncology Centre, Nicosia, CY
N. Pavlidis, University Hospital of Ioannina, GR
R. Popescu, Hirslanden Klinik Aarau, CH
M. Porebiak, SWPS University of Social Sciences and Humanities, Warsaw, PL
C. Sessa, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
C. Sotiriou, Institut Jules Bordet, Brussels, BE
S. Tomic, Clinical Institute of Pathology KBC Split, Split, HR
J.B. Vermorken, Antwerp University Hospital, Edegem, BE
E. Vrdoljak, Clinical Hospital Split, Medical School Split, Split, HR
C. Zielinski, Comprehensive Cancer Center Vienna, Vienna, AT
E. Zucca, Oncology Institute of Southern Switzerland (IOSI), Bellinzona, CH
General information
ORGANISING SECRETARIAT
Dolores Knupfer
European School of Oncology - Bellinzona Office
Piazza Indipendenza 2
CH 6500 Bellinzona - Switzerland
Tel: +41 91 820 0952
Fax: +41 91 820 0953
Email: dknupfer@eso.net
LANGUAGE
The Masterclass will be held in English and translation will not be provided.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants will be advised to take out their own personal and travel insurance coverage.
CME ACCREDITATION AND CERTIFICATE
The 7th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net
The programme has been granted up to 26 European CME credits (ECMEC) . Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.
The programme has also been submitted to ESMO for ESMO-MORA accreditation.
Participants will receive their certificate of attendance via e-mail after the event on completion of the evaluation form.
Application
IDEAL MASTERCLASS CANDIDATE
• Age between 30 and 40 years
• 2-3 years’ experience in oncology
• Involvement in scientific activities and clinical trials
• Fluency in English
PARTICIPATION
Admittance to the Masterclass is by competitive application. The successful applicants are granted free registration, full board, airport transfer to the course venue and accommodation in Vodice for the period 14-19 May 2020. Travel will be covered by the participants.
All participants will be expected to reside at the course venue and their full participation is compulsory throughout the course.
The Masterclass will be taught entirely in English and fluency in English is necessary for admission.
Priority will be given to candidates practicing in Eastern Europe and Balkan region countries.
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (24 JANUARY 2020)
Programme
14 May
18:00 | Registration | |
18:30 | Welcome address and general introduction A. Eniu, CH - N. Pavlidis - GR, E. Vrdoljak, HR |
|
18:45 | Access to care: an old/new issue? Global and Eastern European issues A. Eniu, CH |
|
19:05 | Discussion | |
19:15 | Access to diagnoses and drugs in NSCLC in central and southeastern Europe T. Cufer, SI |
|
19:35 | Discussion |
|
20:00 | Dinner |
15 May
CLINICAL SESSION GENITO-URINARY TUMOURS Chairs: J. Beyer, CH - F.B. Geara, LB |
||
9:00 | Local therapy for prostate cancer (surgery and radiotherapy) F.B. Geara, LB |
|
9:20 | Discussion |
|
9:30 | Metastatic prostate cancer J. Beyer, CH |
|
9:50 | Discussion |
|
10:00 | Testicular cancer J. Beyer, CH |
|
10:20 | Discussion |
|
10:30 | Systemic treatment of advanced renal cancer J. Beyer, CH |
|
10:50 | Discussion |
|
11:00 | Coffee break |
|
11:30 | Tumor board on genito-urinary tumours Faculty |
|
12:15 | Lunch |
|
SPOTLIGHT SESSION 1 |
||
13:30 | How to prepare and deliver a successful public presentation J. Beyer, CH |
|
13:50 | Discussion |
|
14:00 | Statistics in oncology, critical reading clinical trials design and publications… O. Dafni, GR |
|
14:25 | Discussion |
|
14:30 | Coffee break | |
SPOTLIGHT SESSION 2 | ||
15:00 | IPOS lecture: Communication skills as first level psycho-social care M. Porebiak, PL |
|
15:30 | Discussion | |
16:00 -17:15 |
PARTICIPANTS' CASE PRESENTATIONS (3 groups in parallel, 15 cases) T. Cufer, SI - A. Eniu, CH - R. Popescu, CH - N. Pavlidis, GR |
|
20:00 | Dinner |
16 May
SPOTLIGHT SESSION 3 | ||
8:30 | Advances in the management of non-Hodgkin's lymphoma E. Zucca, CH |
|
8:50 | Discussion | |
9:00 | Management of cancer in the elderly E. Brain, FR |
|
9:20 | Discussion | |
CLINICAL SESSION BREAST CANCER Chairs: T. Cufer, SI - E. Vrdoljak, HR |
||
9:30 | Breast cancer pathology and molecular biology S.Tomic, HR |
|
9:50 | Discussion |
|
10:00 | Optimal surgical management of breast cancer M.J. Cardoso, PT |
|
10:20 | Discussion |
|
10:30 | Coffee break | |
11:00 | The role of radiotherapy in early and advanced BC E. Vrdoljak, HR |
|
11:20 | Discussion |
|
11:30 | Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines A. Eniu, CH |
|
11:50 | Discussion |
|
12:00 | Systemic treatment of luminal early and advanced breast cancer A. Eniu, CH |
|
12:20 | Discussion |
|
12:30 | Systemic treatment of HER2-positive early and advanced BC T. Cufer, SI |
|
12:50 | |
Discussion |
13:00 | Lunch | |
14:30 |
Systemic treatment of TN early and advanced BC C. Sotiriou, BE |
|
14:50 | Discussion |
|
15:00 | Cancer genomics for the practising oncologist C. Sotiriou, BE |
|
15:20 | Discussion | |
13:30 | Coffee break |
|
16:00 | Tumor board on breast cancer | |
19:00 | Dinner |
17 May
CLINICAL SESSION GASTRO-INTESTINAL TUMOURS Chairs: S. Cascinu, IT - D. Papamichael, CY |
||
8:30 | Adjuvant/neoadjuvant systemic treatment of colorectal cancer D. Papamichael, CY |
|
8:50 | Discussion | |
9:00 | Systemic treatment of advanced colorectal cancer D. Papamichael, CY |
|
9:20 | Discussion | |
9:30 | Coffee break | |
10:00 | Optimal management of metastatic gastric cancer in 2020 S. Cascinu, IT |
|
10:20 | Discussion | |
10:30 | Adjuvant/neo-adjuvant therapy in GEJ/Stomach adenocarcinoma S. Cascinu, IT |
|
10:50 | Discussion | |
11:00 | Tumour board on gastro-intestinal tumours S. Cascinu, IT - D. Papamichael, CY |
|
11:45 | Lunch |
|
CLINICAL SESSION GYNAECOLOGICAL TUMOURS Chair: C. Sessa, CH |
||
13:00 | Screening of cervical cancer C. Sessa, CH |
|
13:30 | Discussion | |
13:40 | Role of surgery in gynaecological cancer M. Halaska, CZ |
|
14:10 | Discussion | |
14:20 | Systemic management of ovarian cancer J.B. Vermorken, BE |
|
14:50 | Discussion | |
15:00 | Systemic management of cervical and endometrial C. Sessa, CH |
|
15:50 | Discussion | |
16:00 | Coffee break | |
16:15 | Tumor board on gynaecological tumours Faculty |
|
SPOTLIGHT SESSION 4 |
||
17:00 | Therapeutic management of head and neck cancers J.B. Vermorken, BE |
|
17:30 | Discussion | |
17:40 | Tumour board on head and neck cancers J.B. Vermorken, BE |
|
20:00 | Dinner |
18 May
CLINICAL SESSION LUNG CANCER AND MESOTHELIOMA Chairs: T. Cufer, SI, D. Jovanovic, RS |
||
9:00 | Lung cancer pathology and molecular biology I. Kern, SI |
|
9:20 | Discussion | |
9:30 | Surgery for lung cancer and malignant pleural mesothelioma M.A. Hoda, AT | |
9:50 | Discussion | |
10:00 | Optimal management of stage III disease D. Jovanovic, RS | |
Discussion | ||
10:30 | Coffee break | |
11:00 | Targeted agents in NSCLC cancer T. Cufer, SI |
|
11:20 | Discussion | |
11:30 | Standard of care of SCLC and future directions D. Jovanovic, RS |
|
11:50 | Discussion | |
12:00 | Systemic management of mesothelioma D. Jovanovic, RS |
|
12:20 | Discussion | |
12:30 | The diagnostic and therapeutic management of Cancer of Unknown Primary N. Pavlidis, GR |
|
12:50 | Discussion | |
13:00 | Lunch | |
14:30 | Tumor board on lung cancer Faculty |
|
SPOTLIGHT SESSION 5 | ||
15:15 | Systemic management of pancreatic cancer R. Popescu, CH |
|
15:35 | Discussion | |
15:45 | Benefits of early integration of cancer care and palliative care S. Bosnjak, RS |
|
16:05 | Discussion | |
16:15 | Supportive care S. Bosnjak, RS |
|
16:35 | Discussion | |
16:45 | Coffee break | |
15:15- 18:45 |
PARTICIPANTS' CASE PRESENTATIONS (3 groups in parallel, 15 cases) N. Pavlidis, GR - R. Popescu, CH - C. Zielinski, AT |
19 May
SPOTLIGHT SESSION 6 | ||
9:00 | Management of melanoma with immunotherapy and targeted treatment S. Martin-Algarra, ES |
|
9:20 | Discussion | |
9:30 | Learning self-assessment test Chairs |
|
10:20 | Immune check point inhibitors: Immunologic background, indications and innovations C. Zielinski, AT |
|
10:50 | Discussion | |
11:00 | Close Chairs |
|
11:30 | Standing lunch and departures |